| Literature DB >> 28230930 |
Bella B Manshian1, Suman Pokhrel2, Uwe Himmelreich1, Kaido Tämm3, Lauri Sikk3, Alberto Fernández4, Robert Rallo5, Tarmo Tamm6, Lutz Mädler2, Stefaan J Soenen1.
Abstract
Cancer cells have unique but widely varying characteristics that have proven them difficult to be treated by classical therapeutics and calls for novel and selective treatment options. Nanomaterials (NMs) have been shown to display biological effects as a function of their chemical composition, and the extent and exact nature of these effects can vary between different biological environments. Here, ZnO NMs are doped with increasing levels of Fe, which allows to finely tune their dissolution rate resulting in significant differences in their biological behavior on cancer or normal cells. Based on in silico analysis, 2% Fe-doped ZnO NMs are found to be optimal to cause selective cancer cell death, which is confirmed in both cultured cells and syngeneic tumor models, where they also reduce metastasis formation. These results show that upon tuning NM chemical composition, NMs can be designed as a targeted selective anticancer therapy.Entities:
Keywords: ZnO; nanomedicine; nanoparticle; toxic-by-design; tumor therapy
Mesh:
Substances:
Year: 2017 PMID: 28230930 DOI: 10.1002/adhm.201601379
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 9.933